Right-sided ablation to prevent fainting episodes
Official title: Cardio-Neuromodulation in Humans, 3th Study
Run by Imelda Hospital, Bonheiden · NCT04755101 · Data updated 2026-11-12
This study is testing if a new procedure that targets a specific area in the heart can help people with neurally mediated syncope (fainting) have fewer fainting episodes compared to those who receive a placebo.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years and up |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Imelda Hospital, Bonheiden Academic / other |
| Locations | 3 sites (Bonheiden and 2 other locations) |
| Status | Recruiting |
| Started | March 24, 2021 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | April 24, 2025 |
| Trial ID | NCT04755101 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with a history of recurrent syncope and a positive tilt table test indicating a cardioinhibitory or mixed response.
✕Probably not a fit
Patients with syncope due to non-cardiac diseases or those with severe heart conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, double-blind, randomized trial investigates the efficacy and safety of a CT-guided, right-sided ablation of the anterior ganglionated plexus in patients with neurally mediated syncope (NMS). The study aims to determine if this targeted ablation can reduce the recurrence of syncope episodes compared to a sham control group. Participants will undergo assessments of syncope burden and quality of life at multiple follow-up points, and the procedure involves electro-anatomical mapping and pharmacological evaluation. Two-thirds of the participants will receive the active treatment while one-third will receive a placebo.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the frequency of fainting episodes in patients with neurally mediated syncope.
How similar studies have gone: Previous studies on cardioneuroablation have shown promising results, indicating that this approach may be effective, although this specific method is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be in sinus rhythm and have ≥3 syncopes during the last 18 months\* and a previous positive tilt table test (TTT) with a cardioinhibitory or mixed response (VASIS I, IIA or IIB classification). \* syncopes occurring during TTT are not taken into account * Patients have a 'preserved cholinergic SN reserve', defined as ≥20% sinus heart rate increment during a pharmacological test with atropine. Exclusion Criteria: * \<14 years age * Any unstable medical condition, life expectancy \<12 months * Inability to provide consent or undergo follow-up * Syncope due to a non-cardiac disease or due to an advanced neuropathy * Moderate to severe valvular or subvalvular aortic stenosis or mitral stenosis * Overt heart failure or left ventricular ejection fraction \<45% * Current pregnancy * Chronotropic negative medications unless judged mandatory * 4 g amiodarone intake during the 2 months preceding enrollment * Alternating RBBB and LBBB, HV interval \>70 ms * LBBB, bifascicular block (RBBB + LAHB, RBBB + LPHB) * PR interval permanently \>240 ms * Pacemaker or automated implantable cardioverter defibrillator device * Permanent AF, PAF or electrical cardioversion during the last 6 months * Channelopathy * Tilt table test with VASIS III response or with VASIS II response and AV-Block
Where it's running
-
Imeldaziekenhuis
Bonheiden, Belgium Recruiting -
Universitair Ziekenhuis Gasthuisberg
Leuven, Belgium Recruiting -
Algemeen Ziekenhuis Sint Jan
Bruges, Belgium Not yet recruiting
Study contacts
- Principal investigator: Philippe Debruyne, MD — Imeldaziekenhuis
- Study coordinator: Philippe Debruyne, MD
- Email: philippe.debruyne@skynet.be
- Phone: 0032478229896
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Whole-body bedside ultrasound in older adults after a fall
This study tests whether doing a full-body ultrasound at the bedside changes how doctors manage older adults (65+) who come to the emergency department after a fall.
-
Do medicines that lengthen the heart's QT interval cause serious heart problems in hospitalized adults?
This project will test whether commonly used hospital medicines that can prolong the heart's QT interval lead to serious cardiac events in adults admitted to Ontario hospitals.
-
AVEIR leadless pacemaker registry in the United Kingdom
This project will follow people in the UK who receive an AVEIR leadless pacemaker to see how well the device works and how safe it is over five years.
-
AI-based assessment of heart function using ECG wearable monitors
This study tests if a new AI tool using a wearable heart monitor can accurately check heart function in people with heart failure compared to traditional heart scans.
-
24-hour observation for patients with fainting episodes
This study is testing if keeping patients with fainting episodes under observation for 24 hours can help doctors decide when it's safe for them to go home instead of sending them home right away.
-
Evaluating the timing of syncope and asystole during tilt table testing
This study is testing if the timing of fainting during a tilt table test can help predict how well a pacemaker will work for people with reflex syncope.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.